AtriCure, Inc.

AtriCure generates most of its business in the United States, where it has a large direct sales force and where reimbursement policy is especially important to procedure adoption. Internationally, the company sells through direct teams in markets such as Germany, France, the United Kingdom, Benelux, Canada and Australia, and through distributors in Asia, South America and parts of Europe. Management said international revenue grew faster than U.S. revenue in the recent periods, reflecting broad growth across major regions and franchises. Geography matters because the company’s products are procedure-driven, reimbursement-sensitive, and dependent on local regulatory approvals and distributor execution. Currency movements also affect reported growth, which is why management discusses constant-currency performance.

AtriCure faces commercial risk if physicians do not adopt its products broadly enough or if competing technologies gain traction in Afib, appendage management, or pain management. The company’s growth depends on clinical evidence, regulatory approvals, and reimbursement policy, so adverse trial results or unfavorable Medicare coverage could slow procedure volumes. It also relies on direct sales teams, distributors, and key physician relationships, which creates execution risk if training, retention, or channel performance weakens. Supply chain and sterilization dependence is another material risk because interruptions could delay shipments, require redesigns, or trigger FDA re-submissions. More broadly, the medical device market is highly competitive and technologically dynamic, so new products, lower-priced alternatives, or procedure shifts such as PFA catheter adoption can pressure market share and margins.